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The purpose of this study was to determine the eﬀect that concurrent venous thromboembolism (VTE) medications had on early
outcomes following primary total joint arthroplasty (TJA). 2653 total knee and hip arthroplasties were reviewed at a tertiary
medical center. The study performed a multivariable comparison of outcomes in patients on 2 or more VTE medications, as well as
a logistic regression on outcomes following each addition of a VTE medication postoperatively (number of VTE medications was
1–4). Controlling for gender, age, body mass index, and preoperative American Society of Anesthesiologists score throughout the
analysis, patients who received 2 or more VTE prophylaxis medications had increased LOS (p < 0.001), transfusions (p < 0.001),
emergency department visits (p � 0.001), readmissions (p < 0.001), 90dPOE (p < 0.001), and PE (p < 0.001). Every additional
postoperative VTE medication incrementally increased the risk for longer LOS (p < 0.001), transfusions (p < 0.001), 90dPOE
(p < 0.001), deep vein thrombosis (p � 0.049), PE (p < 0.001), emergency department visits (p � 0.005), and readmission
(p � 0.010). Patients on multiple VTE medications following TJA demonstrate signiﬁcantly poorer outcomes. The current study’s
ﬁndings caution the use of multiple VTE medications whenever possible immediately following a TJA.

1. Introduction (DVT: Deep Vein Thrombosis;
PE: Pulmonary Embolism; THA: Total Hip
Arthroplasty; TJA: Total Joint Arthroplasty;
TKA: Total Knee Arthroplasty; VTE:
Venous Thromboembolism)
Since 2013, the number of total joint arthroplasties (TJAs)
performed in the United States exceeds 1,000,000 annually.
Additionally, from 2000 to 2014, the annual volume of total
hip arthroplasties (THAs) increased 132%, and total knee
arthroplasties (TKAs) increased 148% [1]. THA and TKA
are successful surgical procedures in terms of cost-

eﬀectiveness and the impact on the quality of life; however,
complications such as venous thromboembolism (VTE) can
occur perioperatively leading to adverse outcomes [2, 3]. As
a result, postoperative VTE prophylaxis has become routine
following TJA. Without VTE prophylaxis, both THA and
TKA have a deep vein thrombosis (DVT) or pulmonary
embolism (PE) occurrence rate of up to 85% [4]. There is
consensus regarding the need for VTE prophylaxis, but the
method of anticoagulation diﬀers among total joint surgeons. The 2017 American Academy of Orthopedic Surgeons
guidelines for VTE prophylaxis in patients undergoing TKA
and THA recommend a wide array of prophylactic agents,
yet there is no evidence for distinct superiority of a certain
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agent [5, 6]. The survey determined that low-molecularweight heparin, warfarin, aspirin, and fondaparinux were
the most commonly used prophylaxis agents.
Complications after THA and TKA are multifaceted
issues often with signiﬁcant consequences to the patient’s
health, including an increased morbidity and mortality.
Much attention has recently been drawn to these complications as payment structures are evolving towards bundle
payments. In addition to diﬀerent preferences in postoperative VTE prophylaxis, patients who present for a TJA may
have several VTE medications on their medication administration record secondary to comorbidities such as
cardiovascular or cerebrovascular disease. There are currently limited data on the management of postoperative VTE
prophylaxis for patients undergoing TJA who present with
multiple preoperative VTE agents. To date, no study has
compared postoperative outcomes for patients on multiple
VTE medications postoperatively following a total joint
arthroplasty.
The purpose of this study was to determine the eﬀect
concurrent VTE medications had on early outcomes following primary TJA. It is hypothesized that each additional
VTE medication postoperatively increases the patient’s risk
of bleeding events, resulting in longer hospital stays and
increased rates of postoperative complications.

2. Materials and Methods
We performed a retrospective cohort analysis of 2653 patients that underwent TKA and THA by multiple surgeons at
a university aﬃliated, healthcare system in Southeast
Michigan from January 2014 to December 2016. After institutional review board approval, data were standardized
and collected by the study institution for inclusion in the
Michigan Arthroplasty Registry Collaborative Quality
Initiative.
Patient comorbidities were controlled for using the
American Society of Anesthesiologists (ASA) score. Patient
demographics collected in the chart review included age, sex,
body mass index (BMI), preoperative ASA, laterality, and
surgery performed (THA/TKA). Postoperative outcomes
included length of stay (LOS), emergency department visit
with no readmission, readmission (<30 days postoperatively), 90-day postoperative events, intraoperative events,
and postoperative blood transfusion. Postoperative events
included DVT, PE, hematoma, joint space infection, and
death. The VTE prophylaxis agents recorded were aspirin,
unfractionated or low-molecular-weight heparin, direct
thrombin or factor Xa inhibitor, other antiplatelets, and
warfarin.
The inclusion criteria consisted of primary joint replacement (THA or TKA). The study excluded partial joint
arthroplasty, arthroplasty due to a traumatic event, revision
arthroplasty, and patients who underwent multiple joint
replacements within the selected period.
Postoperatively, patients received 24 hours of antibiotic
prophylaxis and were mobilized with physical therapy on
postoperative day 0-1. Patients received tranexamic acid per
hospital protocol. The protocol consists of 1 g of intravenous
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tranexamic acid before incision in hips or closure of the
incision. If patients had contraindication to intravenous
tranexamic acid, then 2 g of topical tranexamic acid was
placed into the incision at the time of closure. During the
time period of the study, patients were transfused when
hemoglobin was less than 8 mg/dL if symptomatic or if
hemoglobin was less than 7 mg/dL. Each patient’s postoperative anticoagulation followed the hospital protocol.
Throughout the study period following surgery, all patients received at least one VTE prophylaxis medication, a
sequential compression device, and early mobilization, per
institutional protocol. Patients at the tertiary medical center
with no history of prior DVT or PE were given aspirin 81 mg
twice a day for 4 weeks starting postoperative day 0. If the
patient could not take aspirin, then they received enoxaparin
40 mg daily for 3 weeks. High-risk patients were given
enoxaparin 30 mg twice a day for 4 weeks. If the patient was
on warfarin at home, then enoxaparin 40 mg daily was
administered on postoperative day 1, and warfarin was
restarted on postoperative day 0. Enoxaparin was discontinued once international normalized ratio was at a
therapeutic level (2.5). Patients on a factor Xa inhibitor were
given half the dose on postoperative day 1 and transitioned
to a full dose on postoperative day 7.
Patients were seen by either their primary care physician,
an optimization clinic, or a specialist (i.e., cardiology) preoperatively before undergoing TJA. At this appointment,
basic preoperative labs including complete blood count, basic
metabolic proﬁle, and coagulation proﬁle were part of determining a patient’s health status. A patient was deemed
acceptable for elective surgery with hemoglobin above 10 gm/
dL with a surgical preference of 12 gm/dL. A patient’s coagulopathy was corrected preoperatively based on an INR level
less than 2. Finally, a patient was considered optimal with a
platelet count of greater than 100,000 platelets per microliter,
and if below, it had to be cleared with a hematologist.
2.1. Statistical Analysis. All statistical tests were run on
SigmaStat 12.3 (Systat Software Inc., San Jose, CA). Alpha in
all cases was set to 0.05. Continuous variables (BMI, age, and
preoperative ASA score) were examined as parametric Ttests and as nonparametric rank-sum tests. Categorical
variables (case joint, side, race, gender, and preoperative
ASA score) were examined as chi-square analyses.
Risk factors, considered as binary output variables (LOS,
considered as above or below the median value for this cohort,
transfusion, emergency department visit, 30-day readmission,
urinary tract infection, DVT, PE, hematoma, joint space infection, other reason for returning to the operating room, or
death), were examined as multiple logistic regressions, taking
into account BMI, age, gender, preoperative ASA score, and
number of VTE medications. A similar analysis was performed,
instead examining the eﬀect of 1 versus 2 or more postoperative
VTE medications. Finally, the analysis was performed again,
examining the eﬀect of the total number of postoperative VTE
medications used (considered as a continuous variable). For this
analysis, LOS (days) was also considered as a continuous variable
in a multiple linear regression.
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3. Results
A total of 2653 participants underwent primary THA or
TKA during the study period. The study group consisted of
1666 TKAs (62.8%) and 987 THAs (37.2%). Eight hundred
eighty-one patients received multiple VTE prophylaxis
medications postoperatively (33.2%; 537 TKAs and 344
THAs), while 1772 received only 1 modality (66.8%; 1129
TKAs and 643 THAs) (Table 1).
Demographic data (BMI, case joint, side, race, gender,
age, and preoperative ASA score) were compared between
patients who received 2 or more inpatient prophylaxis
(Table 2). Patients on 2 or more VTE medications postoperatively were more likely to be older (p < 0.001) and have
a higher preoperative ASA score (p < 0.001).
After controlling for gender, age, BMI, and preoperative
ASA score, patients who received 2 or more medications for
VTE prophylaxis had an increased LOS (OR: 2.305,
p < 0.001) as well as signiﬁcant risk for 90-day postoperative
events (OR: 0.595, p < 0.001) and PE (OR: 9.225, p < 0.001)
(Table 3). These patients were also twice as likely to be
transfused (1.993, p < 0.001) and had a higher occurrence of
emergency department visits without readmission (OR:
1.546, p � 0.001) and readmissions (OR: 1.799, p < 0.001).
Interestingly, there were 144 patients of the 881 patients
receiving multiple VTE prophylaxis medications who received 3 or 4 diﬀerent modalities. Of those patients, 131
(91.0%) of them were recorded to have 3 or more VTE
prophylaxis medications.
Continuing to control for BMI, age, gender, and preoperative ASA score, for every additional postoperative VTE
medication, ranging 1 to 4, the risk for longer LOS (2.039,
p < 0.001), chances for inpatient transfusion (1.646,
p < 0.001), 90-day postoperative events (1.325, p < 0.001),
DVT (1.541, p � 0.049), PE (8.147, p < 0.001), emergency
department visit (1.329, p � 0.005), and readmission (1.379,
p � 0.010) incrementally increased (Table 4).

4. Discussion
As the number of TJAs continues to increase, it is important
to continue to stratify patients and reduce postoperative
complications, especially as the emphasis for value-based
care drives the healthcare system. This multivariate analysis
demonstrated that patients on multiple VTE prophylaxis
agents postoperatively were at increased risk for complications after TJA. In addition, patients receiving 2 or more
VTE prophylaxis agents postoperatively demonstrated increased LOS as well as increased rates of postoperative
transfusion, urinary tract infection, PE, emergency department visits without readmission, and readmission. The logistic regression analysis demonstrated that these risks
increase for every additional prophylactic VTE medication.
These ﬁndings demonstrate a subset of patients that can
potentially be optimized further prior to TJA in order to reduce
the risk of increased morbidity and cost. Referencing a study
published in the Journal of Thrombosis and Hemostasis seeking
to objectively deﬁne major bleeding in surgical patients, this
study did ﬁnd an association with an increased rate of
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transfusion in patients on 2 or more anticoagulants postoperatively [7]. Hallevi and collaborators compared diﬀerent
regimens for starting long-term anticoagulation after cardioembolic stroke and found that enoxaparin or heparin
bridging increased bleeding risks in cardioembolic stroke
patients [8]. Similar to this study, Leijtens et al. found an
increased risk of transfusion, hematoma, readmission, LOS,
and periprosthetic joint infection in their patients requiring
perioperative heparin bridging [9]. In TJA patients requiring
blood transfusion, one study found a signiﬁcant association
between blood transfusion and risk of periprosthetic joint
infection [10]. Ferraris et al. presented the risks that come with
intraoperative and postoperative transfusion. Not only are
patients exposed to increased risks of allergic reactions, infectious diseases, lung injury, and hemolytic reactions but also
patients who received a transfusion postoperatively had adverse health outcomes, such as increased mortality [11]. With
any TJA, the risk of VTE must be balanced with the risk of
bleeding complications [12–18]. Patients should be counseled
on these risks, and further research is required to continue to
decrease this risk. This study demonstrated that transfusion
rates were increased with every additional VTE medication that
patients took postoperatively.
The emphasis on value-based healthcare continues to
increase. This study demonstrated several postoperative
events including increased length of stay, postoperative ED
visits, and readmission rates that have been heavily scrutinized in the arthroplasty literature due to the higher costs on
the healthcare. Surgical complications cause readmission to
cost an average of $45,901 for TKA and $31,880 for THA
[19]. Due to the current reimbursement policy, hospitals
receive an average reimbursement of $9,423 from Medicare/
Medicaid for TKA and $20,517 for THA [19]. Concomitantly, Chen et al. investigated costs of transfusion postoperatively after total knee and hip arthroplasties [16]. They
demonstrated that patients who received blood transfusions
after TKA ($61,548.25) were higher than those that did not
receive blood transfusions ($51,768.58), and hips were
$82,588.60 versus $64,845.60. They correlated this increase
cost with an increased LOS, which is similar to the ﬁndings
of this study. Moreover, postoperative ED visits with or
without readmission greatly increase the cost of TJA [20, 21].
Unfortunately, many of the current bundling models are
limited in the risk-adjustment techniques for factors such as
increased ASA score, preoperative therapy, and subsequent
major complications. Thus, the onus falls on the surgical
team to optimize patients prior to TJA in order to decrease
the cost associated with the surgical episode. As the
healthcare landscape continues to change, mitigation of
these risks will be of utmost importance. Further studies will
be needed in order to evaluate the cost savings associated
with patient optimization prior to TJA.
There are several limitations to the present study. Since
there is a low occurrence of the complications studied, a
cohort size of 2653 provides adequate power to ﬁnd a difference. Yet since, the lowest possible population expected to
produce a clinical diﬀerence was not calculated, one may
dispute signiﬁcant diﬀerences as this cohort size may not be
strong enough. A retrospective study always has its
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Table 1: Postoperative anticoagulants prescribed.

Number of postoperative VTE
medications

Aspirin

Unfractionated heparin or Direct factor Xa or II
LMWH
inhibitor

995
(56.2%)
539
(73.1%)
125
(90.6%)
6 (100%)

1
2
3
4

Antiplatelet
excluding ASA

Warfarin

Total
patients

158 (8.9%)

1772

119 (6.7%)

519 (29.3%)

0

737 (100%)

371 (50.3%)

0

134 (97.1%)

26 (18.8%)

1 (0.7%)

6 (100%)

5 (83.3%)

1 (16.7%)

280
(38.0%)
128
(92.8%)
6 (100%)

737
138
6

Table 2: Demographics of patients on 2 or more VTE medications postoperatively.
Parameter

Test
T-test
Rank sum

p value
0.122
0.100

Case joint

Chi-square

0.165

Side

Chi-square

0.987

Race

Chi-square

0.996

Gender

Chi-square

0.143

Age

T-test
Rank sum

<0.001
<0.001

Preoperative ASA (categorical)

Chi-square

<0.001

Preoperative ASA (continuous)

T-test
Rank sum

<0.001
<0.001

Body mass index

2 or more inpatient prophylaxis (N � 881)
31.6 (6.5)
30.8 (27.1–35.5)
TKA � 537
THA � 344
Left � 408
Right � 455
Both � 18
Caucasian � 732
AA � 111
Unknown � 38
Male � 374
Female � 507
68.6 (10.1)
69.0 (62.0–76.0)
1�3
2 � 156
3 � 625
4 � 96
2.9 (0.5)
3.0 (3.0–3.0)

Others (N � 1779)
32.1 (6.7)
31.2 (27.4–36.4)
TKA � 1135
THA � 644
Left � 821
Right � 923
Both � 35
Caucasian � 1476
AA � 226
Unknown � 76
Male � 701
Female � 1078
64.7 (10.4)
65.0 (58.0–72.0)
1 � 17
2 � 489
3 � 1165
4 � 107
2.8 (0.6)
3.0 (2.0–3.0)

AA: African American; ASA: American Society of Anesthesiologists; THA: total hip arthroplasty; TKA: total knee arthroplasty; VTE: venous thromboembolism. Patients on 2 or more VTE medications postoperatively were more likely to be older and have a higher preoperative ASA score.

Table 3: Multivariate analysis of 2 or more venous thromboembolism medications postoperatively.
Factors
Length of stay (logistic regression)
Transfusion
Emergency department visit
30-day readmission
90-day postoperative events
Urinary tract infection
Deep venous thrombosis
Pulmonary embolism
Hematoma
Joint space infection
Other return to the operating room
Death

Lower
1.855
1.439
1.186
1.288
1.268
1.063
0.559
2.586
0.802
0.785
0.676
0.25

Upper
2.863
2.761
2.015
2.511
1.516
8.379
1.976
32.901
3.793
4.752
1.772
13.4

Odds
2.305
1.993
1.546
1.799
1.405
2.984
1.051
9.225
1.744
1.931
1.095
1.829

p value
<0.001
<0.001
<0.001
<0.001
0.001
0.038
0.878
<0.001
0.161
0.152
0.712
0.552

Controlling for gender, age, joint, BMI, and preoperative ASA, patients on multiple anticoagulants in the hospital were at an increased risk for length of stay,
pulmonary embolism, no 90-day postoperative events, readmission, and transfusion.

limitations. The collected information cannot be veriﬁed for
accuracy, which is based on the health professional who
recorded the information. Along with the collection of large
databases, the dose and frequency of the medications cannot
be veriﬁed for more accurate conclusions between diﬀerent

strengths and dose eﬀects. Finally, discrete laboratory values
preoperatively were not collected, and this is certainly a
limitation of this retrospective review. This limitation does
not allow the authors to deﬁnitely conclude the incidence of
patients undergoing TJA with laboratory values that did not
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Table 4: Logistic regression analysis on increasing the number of VTE medications postoperatively.
Risk factors
BMI

Gender (female)

Age

ASA score

0.002 (1.021,
1.008–1.035)

<0.001 (2.208,
1.861–2.620

<0.001 (1.042,
1.033–1.051)

0.719

0.315

0.876

<0.001 (1.680,
1.435–1.966)
0.014 (0.789
0.653–0.954)

Inpatient postoperative
prophylaxis count
<0.001 (2.039,
1.747–2.378)
<0.001 (0.675,
0.578–0.789)

0.629

0.772

0.525

0.223

0.005 (1.329, 1.088–1.623)

Readmit

0.465

0.416

DVT
UTI

0.120
0.962

0.504
0.448

0.010 (1.023,
1.006–1.041)
0.184
0.267

0.049 (1.541, 1.002–2.371)
0.011 (2.306, 1.212–4.389)

Death

0.954

0.309

0.598

0.002 (1.668,
1.215–2.292)
0.774
0.444
0.003 (33.409,
3.318–336.402)

PE

0.183

0.761

0.706

0.186

<0.001 (8.147,
4.205–15.785)

0.028 (1.713,
1.059–2.773)
0.669
0.911

0.003 (0.967,
0.946–0.989)
0.685
0.122

0.786

0.331

0.163

0.252

0.333
0.371
0.002 (1.611,
1.184–2.193)

0.282
0.543
<0.001 (1.646,
1.308–2.072)

Event
Length of stay (logistic
regression)
No 90-day
postoperative events
Emergency department
visit

Other return to the
operating room
Hematoma
JSI
Transfusion

0.525
0.155
0.225
<0.001 (0.943,
0.918–0.969)

0.010 (1.379, 10.78–1.762)

0.897

Single values represent odds ratios. Multiple values represent p value (odds ratio, conﬁdence interval). ASA: American Society of Anesthesiologists; BMI:
body mass index; DVT: deep vein thrombosis; JSI: joint space infection; PE: pulmonary embolism; UTI: urinary tract infection; VTE: venous thromboembolism. Controlling for BMI, gender, age, and preoperative ASA score, additional postoperative VTE medication, ranging 1 to 4, incrementally increases
the risk for longer length of stay, chances for inpatient transfusion, 90-day postoperative event, DVT, PE, emergency department visit, and readmission.

meet the health system protocol stated in the methods
section. A strength of this study is that this study received no
industry funding or support.

5. Conclusions
This study identiﬁed the association of administering multiple
antithrombotic agents postoperatively with an increased rate
of poor postoperative outcomes following TJA. The results
demonstrate the ﬁne balance between the need for VTE
prophylaxis and the risk for other postoperative complications. It reinforces this balance by demonstrating that patients
on multiple VTE medications postoperatively have a signiﬁcantly higher risk for a PE and DVT, and patients on 2 or
more VTE modalities have an increased risk of transfusion.
Logistic regression suggests that if patients receiving 2 or
more VTE modalities decreased 1 pharmacologic agent, their
risk of a transfusion, emergency department visit without
readmission, and readmission would signiﬁcantly decrease.
All of the ﬁndings demonstrate that additional VTE prophylaxis postoperatively has a signiﬁcant eﬀect in outcomes
following TKA and THA.

Data Availability
The data that support the ﬁndings of this study are available
from the corresponding author, LW, upon reasonable
request.
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consultation phone service for patients with total joint
arthroplasty may reduce unnecessary emergency department
visits,” The Journal of Arthroplasty, vol. 33, no. 3, pp. 650–654,
2018.

Advances in Orthopedics

